-
FDA Approves Tyenne
FDA Approves Tyenne
2024-03-08 -
FDA Approves Wyost (denosumab-bddz), an Interchangeable Biosimilar to Xgeva
FDA Approves Wyost (denosumab-bddz), an Interchangeable Biosimilar to Xgeva
2024-03-08 -
FDA Approves Jubbonti (denosumab-bddz), an Interchangeable Biosimilar to Prolia
FDA Approves Jubbonti (denosumab-bddz), an Interchangeable Biosimilar to Prolia
2024-03-08
New Products
Changzhou Extraordinary Pharmatech co., LTD.
Changzhou Extraordinary Pharmatech co., Mg, grams, kilograms, tonnage pharmaceutical intermediates, customized production;Sales of various chemical test and agent catalysts.
Company has strong ability of research and development, has multi-function production workshop, at the same time with high temperature and high pressure, temperature, such as small and medium-sized reactor,And equipped with a gas chromatograph (GC), high performance liquid chromatograph (HPLC) analysis of testing instruments, such as,Meet from mg、kg、ton identifying and customization of rare compounds screening, can accept FTE, CRO the custom synthesis,process optimization, route design, technology outsourcing services,with the domestic many scientific research institutions and r&d team to develop, in the chemical industry park and dozens of chemical plants have long-term cooperative relations, and in hubei, jiangxi, shandong has a processing base, provides the guarantee to provide a steady stream of supply of goods.
We have our own factories and laboratories.We focus on technology and services.I hope we have the opportunity to cooperation.
We will give you the best price and service.
Welcome to the advisory prices.